GLP-1 Agonists Are Changing Weight Loss in Canada, But Medication Alone Is Not Enough
Canada is entering a new era in obesity and diabetes treatment. In April 2026, Health Canada became the first G7 regulator to approve a generic version of semaglutide injection, which is the medication most people recognize under the brand name Ozempic. This marks a major milestone for accessibility and affordability while signalling how rapidly GLP-1 agonists are reshaping metabolic healthcare across the country.
As a nutrition strategist and gut health practitioner, I see both the incredible potential of these medications and the important gaps in how they are often discussed online. GLP-1 agonists can be powerful tools, but they are not magic. Without proper nutrition, resistance training, and long-term lifestyle support, many people risk losing significant muscle mass during treatment and regaining weight once the medication is stopped. Understanding how these medications work and how nutrition can support better outcomes is essential.
What Are GLP-1 Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a naturally occurring hormone involved in blood sugar regulation, appetite control, and digestion. These medications work through several complementary mechanisms:
They stimulate insulin secretion after meals, which helps lower blood glucose levels.
They reduce glucagon secretion, which decreases glucose release from the liver.
They slow gastric emptying, which helps people feel fuller for longer.
They influence appetite-regulating centres in the brain to reduce hunger and food cravings.
They may improve metabolic markers such as triglycerides, LDL cholesterol, inflammation, and ectopic fat accumulation.
One of the reasons GLP-1 medications are considered safer than some older diabetes medications is their glucose-dependent action. They increase insulin secretion primarily when blood sugar levels are elevated, which lowers the risk of hypoglycemia when used alone. While these medications were initially developed for type 2 diabetes management, their effects on appetite and body weight rapidly transformed obesity treatment.
Canada’s Historic Approval of Generic Semaglutide
In April 2026, Health Canada approved the first generic semaglutide injection in the G7, submitted by Dr. Reddy's Laboratories. This generic product was approved as equivalent to the brand-name medication Ozempic. This matters because cost has been one of the biggest barriers to treatment access. Generic medications in Canada are often 45 to 90% less expensive than their brand-name counterparts, which potentially makes GLP-1 therapies accessible to far more Canadians.
Health Canada also approved oral semaglutide tablets under Rybelsus earlier in 2026, which marks another major shift in how these medications can be delivered. These approvals are likely only the beginning. As patents expire and competition increases, we will probably see broader access to GLP-1 therapies over the next several years.
The Problem that needs to be talked About
Much of the conversation around GLP-1 agonists focuses on rapid weight loss, but an important detail is often overlooked because not all weight loss is beneficial. When calorie intake drops significantly, as commonly happens on GLP-1 medications due to appetite suppression, the body does not lose only fat mass. It can also lose lean body mass, including skeletal muscle.
This matters because muscle is a metabolically active tissue that supports metabolic health, blood sugar regulation, physical strength, and bone health. Research suggests that a meaningful proportion of weight lost on GLP-1 medications may come from lean tissue if nutrition and exercise are not carefully addressed. For many people, appetite suppression becomes so strong that they unintentionally under-eat protein, fibre, and total calories. This can lead to skipping meals entirely or relying on highly processed foods that feel easier to tolerate while nauseated, which becomes problematic very quickly from a nutritional perspective.
Why Nutrition Support During GLP-1 Treatment Is Essential
GLP-1 medications change appetite, but they do not automatically teach sustainable eating habits, improve nutritional adequacy, or preserve muscle mass. This is where individualized nutrition counselling becomes critical. A well-designed nutrition strategy during GLP-1 treatment should prioritize several key areas:
Adequate Protein Intake: Protein becomes especially important during rapid weight loss because sufficient intake helps preserve lean muscle mass and supports recovery, satiety, and metabolic function.
Resistance Training: Exercise is not optional during medically assisted weight loss. Strength training helps signal the body to preserve muscle tissue during caloric deficits, whereas the body is more likely to break down muscle alongside fat stores without this stimulus.
Fibre and Gut Health: GLP-1 medications commonly cause digestive side effects such as constipation, bloating, and nausea. Nutrition strategies that support fibre intake, hydration, and microbiome health can help improve tolerance and digestive comfort.
Long-Term Behaviour Change: One of the biggest misconceptions is the idea that these medications fix weight regulation permanently. For many individuals, weight regain occurs after discontinuation if sustainable habits were never developed. Medication creates a valuable therapeutic window, but long-term outcomes still depend heavily on behaviour, nutrition quality, sleep, and stress management.
Weight Regain After Stopping GLP-1 Medications
This is one of the most important conversations patients deserve to have before starting treatment. If someone loses weight primarily through severe caloric restriction without building sustainable habits, there is a high likelihood of regaining weight after discontinuation. In many cases, people regain fat more rapidly than muscle, which can negatively affect body composition and metabolic health over time. This does not mean GLP-1 medications are ineffective, but rather that they work best when combined with comprehensive lifestyle support rather than used in isolation.
A More Sustainable Approach
GLP-1 agonists represent a major advancement in metabolic medicine. For many individuals with obesity, insulin resistance, or type 2 diabetes, these medications can significantly improve quality of life. However, the goal should not simply be a lower body weight. Instead, the focus should be on better metabolic health, preserved muscle mass, and sustainable eating patterns.
As Canada expands access to generic semaglutide and other GLP-1 therapies, we also need to expand the conversation around what truly successful treatment looks like. Lasting metabolic health is built through much more than appetite suppression alone.
At Arandu Nutrition, I work with clients to create sustainable, microbiome-supportive nutrition strategies that help protect muscle mass, support metabolic health, and improve digestion. My approach combines evidence-based nutrition science with practical, individualized coaching designed to support real life rather than short-term restriction. Whether you are currently using a GLP-1 medication, considering one, or transitioning off treatment, professional nutrition support can make a meaningful difference in how your body responds during every stage of the process.
Send me a message or book a FREE discovery consultation to see how I can support you during treatment or after treatment to ensure results are optimal and lasting!